Dyne Therapeutics (NASDAQ:DYN) Upgraded at Raymond James

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) was upgraded by equities research analysts at Raymond James to a "strong-buy" rating in a research note issued to investors on Thursday,Zacks.com reports.

DYN has been the topic of several other reports. Royal Bank of Canada began coverage on Dyne Therapeutics in a research report on Tuesday, November 26th. They set an "outperform" rating and a $45.00 price objective on the stock. Chardan Capital reiterated a "buy" rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. Guggenheim increased their price objective on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a "buy" rating in a research report on Thursday, August 15th. Piper Sandler reaffirmed an "overweight" rating and issued a $53.00 target price on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Finally, StockNews.com lowered shares of Dyne Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday, September 16th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $50.42.

Dyne Therapeutics Trading Up 0.5 %

NASDAQ:DYN traded up $0.12 during trading hours on Thursday, reaching $25.73. 840,351 shares of the company traded hands, compared to its average volume of 1,445,920. Dyne Therapeutics has a 1 year low of $11.51 and a 1 year high of $47.45. The stock has a market capitalization of $2.62 billion, a P/E ratio of -7.23 and a beta of 1.09. The business's 50-day moving average price is $30.39 and its two-hundred day moving average price is $35.20.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.25). As a group, equities analysts anticipate that Dyne Therapeutics will post -3.45 EPS for the current year.

Insider Activity at Dyne Therapeutics

In related news, insider Oxana Beskrovnaya sold 2,339 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total transaction of $80,812.45. Following the completion of the transaction, the insider now directly owns 140,375 shares of the company's stock, valued at approximately $4,849,956.25. This represents a 1.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Susanna Gatti High sold 8,976 shares of the firm's stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total value of $308,864.16. Following the transaction, the chief operating officer now owns 131,636 shares of the company's stock, valued at $4,529,594.76. This represents a 6.38 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 180,046 shares of company stock valued at $6,300,265. 20.77% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. SG Americas Securities LLC purchased a new position in Dyne Therapeutics in the second quarter worth about $217,000. Nisa Investment Advisors LLC increased its position in shares of Dyne Therapeutics by 904.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company's stock valued at $26,000 after purchasing an additional 669 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Dyne Therapeutics by 52.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 311,504 shares of the company's stock valued at $10,993,000 after purchasing an additional 107,233 shares during the last quarter. Legato Capital Management LLC raised its holdings in Dyne Therapeutics by 35.3% during the 2nd quarter. Legato Capital Management LLC now owns 15,480 shares of the company's stock valued at $546,000 after buying an additional 4,035 shares during the period. Finally, Lisanti Capital Growth LLC lifted its position in Dyne Therapeutics by 22.5% in the second quarter. Lisanti Capital Growth LLC now owns 106,140 shares of the company's stock worth $3,746,000 after buying an additional 19,530 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.